Sign up to save your podcasts
Or
Share Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.
Join us as we discuss:
• The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them.
• The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies.
• Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival.
• Insights into the CNS activity of these treatments and the common side effects patients may experience.
• Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors.
Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.
https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#entrectinib #larotrectinib #repotrectinib
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.
Join us as we discuss:
• The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them.
• The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies.
• Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival.
• Insights into the CNS activity of these treatments and the common side effects patients may experience.
• Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors.
Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.
https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#entrectinib #larotrectinib #repotrectinib
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,358 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners